News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ)'s Zytiga Helps Eliminate Early-Stage Prostate Cancer


5/17/2012 7:44:04 AM

Johnson & Johnson (JNJ)’s Zytiga, approved last year to treat metastatic prostate cancer, helped eliminate tumors in high-risk patients whose malignancy hadn’t yet spread, a small study found. The pill was given as an initial therapy before surgery to 58 patients with aggressive tumors that were confined to the prostate gland, a group typically treated with radiation. These patients are rarely cured by surgery and previous studies using older drugs failed to improve survival, said Mary-Ellen Taplin, an associate professor at Harvard Medical School in Boston.

Read at Bloomberg
Read at Reuters
Read at Fox News
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES